Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
GCA
•
Large vessel vasculitis
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
Is there benefit of addition of a DMARD such as methotrexate? Would you revisit diagnosis?
Related Questions
Would you add a DMARD such as methotrexate for a patient with GCA and partial response to tocilizumab but inability to taper prednisone below 10mg daily?
What biologic or conventional/synthetic DMARD would you use as a steroid sparing agent in a patient with GCA and a history of diverticulitis?
How do you treat IgA vasculitis with gastrointestinal involvement?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
How do you approach management of recurrent idiopathic pleuropericarditis?
Do you have to extend treatment for acute Lyme disease if a patient is on high dose steroids for another indication?
In a patient with sicca symptoms and SS-B antibodies only, can a minor salivary gland lip biopsy with lymphoid aggregates, but also scattered areas of acute neutrophilic inflammation be consistent with Sjogren's Disease?
How would you treat a patient with osteoarthritis of just one joint of the hand?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?